Abstract
BackgroundActivation and coagulation biomarkers were measured within the Strategies for Management of Antiretroviral Therapy (SMART) trial. Their associations with opportunistic disease (OD) in human immunodeficiency virus (HIV)–positive patients were examinedMethodsInflammatory (high-sensitivity C-reactive protein [hsCRP], interleukin-6 [IL–6], amyloid-A, and amyloid-P) and coagulation (D-dimer and prothrombin-fragment 1+2) markers were determined. Conditional logistic regression analyses were used to assess associations between these biomarkers and risk of ODResultsThe 91 patients who developed an OD were matched to 182 control subjects. Patients with an hsCRP level ⩾5 μg/mL at baseline had a 3.5 higher odds of OD (95% confidence interval [CI], 1.5–8.1) than did those with an hsCRP level
Original language | English |
---|---|
Pages (from-to) | 973-983 |
Journal | The Journal of infectious diseases |
Volume | 200 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2009 |